Bellerophon Therapeutics, Inc. (BLPH)

The chart shows the growth of $10,000 invested in Bellerophon Therapeutics, Inc. in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $481 for a total return of roughly -95.19%. All prices are adjusted for splits and dividends.

Bellerophon Therapeutics, Inc. had a return of 618.89% year-to-date (YTD) and 249.73% in the last 12 months. Over the past 10 years, Bellerophon Therapeutics, Inc. had an annualized return of -31.31%, while the S&P 500 had an annualized return of 8.04%, indicating that Bellerophon Therapeutics, Inc. did not perform as well as the benchmark.

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Bellerophon Therapeutics, Inc. Sharpe ratio is 1.15. A Sharpe ratio greater than 1.0 is considered acceptable.

The chart below displays rolling 12-month Sharpe Ratio.

The Drawdowns chart displays portfolio losses from any high point along the way.

The table below shows the maximum drawdowns of the Bellerophon Therapeutics, Inc.. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Bellerophon Therapeutics, Inc. is 99.63%, recorded on Dec 20, 2022. The portfolio has not recovered from it yet.

Current Bellerophon Therapeutics, Inc. volatility is 211.52%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.